Marshall Wace LLP Sells 426,575 Shares of IQVIA Holdings Inc. $IQV

Marshall Wace LLP reduced its position in IQVIA Holdings Inc. (NYSE:IQV) by 54.9% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 350,199 shares of the medical research company’s stock after selling 426,575 shares during the period. Marshall Wace LLP owned 0.21% of IQVIA worth $55,188,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Clal Insurance Enterprises Holdings Ltd boosted its position in shares of IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after purchasing an additional 131 shares in the last quarter. Trust Co. of Toledo NA OH purchased a new position in shares of IQVIA in the 2nd quarter valued at approximately $39,000. J.Safra Asset Management Corp boosted its stake in IQVIA by 208.6% in the 2nd quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock worth $39,000 after purchasing an additional 169 shares in the last quarter. Rothschild Investment LLC increased its stake in IQVIA by 85.5% during the 2nd quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 124 shares in the last quarter. Finally, NewSquare Capital LLC raised its stake in IQVIA by 185.3% in the 2nd quarter. NewSquare Capital LLC now owns 291 shares of the medical research company’s stock worth $46,000 after acquiring an additional 189 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Performance

Shares of IQVIA stock opened at $225.68 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $234.29. The firm’s 50-day simple moving average is $214.48 and its 200-day simple moving average is $186.71. The firm has a market cap of $38.43 billion, a PE ratio of 30.96, a price-to-earnings-growth ratio of 2.53 and a beta of 1.37.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. The firm had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. IQVIA’s revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This trade represents a 12.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Morgan Stanley boosted their price target on IQVIA from $250.00 to $265.00 and gave the company an “overweight” rating in a report on Monday, December 1st. Robert W. Baird set a $258.00 price objective on shares of IQVIA and gave the company an “outperform” rating in a report on Wednesday, October 29th. Redburn Partners set a $214.00 target price on IQVIA in a report on Wednesday, September 3rd. Cowen downgraded IQVIA from a “buy” rating to a “hold” rating in a report on Monday, November 3rd. Finally, Baird R W upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 29th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $241.44.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.